Aurinia Pharmaceuticals (AUPH) Competitors $12.09 +0.08 (+0.67%) Closing price 04:00 PM EasternExtended Trading$12.15 +0.06 (+0.50%) As of 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AUPH vs. RNA, NUVL, AXSM, CRSP, MRUS, ABVX, VKTX, TGTX, ACAD, and KRYSShould you be buying Aurinia Pharmaceuticals stock or one of its competitors? The main competitors of Aurinia Pharmaceuticals include Avidity Biosciences (RNA), Nuvalent (NUVL), Axsome Therapeutics (AXSM), CRISPR Therapeutics (CRSP), Merus (MRUS), Abivax (ABVX), Viking Therapeutics (VKTX), TG Therapeutics (TGTX), ACADIA Pharmaceuticals (ACAD), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry. Aurinia Pharmaceuticals vs. Its Competitors Avidity Biosciences Nuvalent Axsome Therapeutics CRISPR Therapeutics Merus Abivax Viking Therapeutics TG Therapeutics ACADIA Pharmaceuticals Krystal Biotech Avidity Biosciences (NASDAQ:RNA) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends. Is RNA or AUPH more profitable? Aurinia Pharmaceuticals has a net margin of 23.31% compared to Avidity Biosciences' net margin of -4,247.77%. Aurinia Pharmaceuticals' return on equity of 20.06% beat Avidity Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Avidity Biosciences-4,247.77% -33.45% -30.22% Aurinia Pharmaceuticals 23.31%20.06%13.81% Do institutionals and insiders have more ownership in RNA or AUPH? 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 3.8% of Avidity Biosciences shares are owned by insiders. Comparatively, 12.2% of Aurinia Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more risk & volatility, RNA or AUPH? Avidity Biosciences has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Do analysts recommend RNA or AUPH? Avidity Biosciences presently has a consensus price target of $67.00, indicating a potential upside of 45.43%. Aurinia Pharmaceuticals has a consensus price target of $12.00, indicating a potential downside of 0.74%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Avidity Biosciences is more favorable than Aurinia Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avidity Biosciences 0 Sell rating(s) 0 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 3.06Aurinia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation & earnings, RNA or AUPH? Aurinia Pharmaceuticals has higher revenue and earnings than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvidity Biosciences$10.90M543.75-$322.30M-$3.00-15.36Aurinia Pharmaceuticals$235.13M6.77$5.75M$0.4328.12 Does the media prefer RNA or AUPH? In the previous week, Avidity Biosciences had 27 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 29 mentions for Avidity Biosciences and 2 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 1.28 beat Avidity Biosciences' score of 0.54 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avidity Biosciences 10 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aurinia Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAurinia Pharmaceuticals beats Avidity Biosciences on 11 of the 17 factors compared between the two stocks. Get Aurinia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AUPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AUPH vs. The Competition Export to ExcelMetricAurinia PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.59B$2.46B$5.60B$9.82BDividend YieldN/A1.68%4.60%4.11%P/E Ratio28.1222.0530.2825.72Price / Sales6.77484.49426.2096.43Price / Cash36.70183.0237.7558.93Price / Book4.744.718.456.01Net Income$5.75M$31.61M$3.25B$265.06M7 Day Performance5.77%3.93%4.05%2.80%1 Month Performance33.74%3.32%4.27%1.65%1 Year Performance116.28%13.53%36.25%29.33% Aurinia Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AUPHAurinia Pharmaceuticals2.8292 of 5 stars$12.09+0.7%$12.00-0.7%+120.4%$1.59B$235.13M28.12300Positive NewsRNAAvidity Biosciences2.913 of 5 stars$45.75-1.2%$67.00+46.4%+3.0%$5.51B$8.93M-15.25190Upcoming EarningsAnalyst RevisionNUVLNuvalent3.1076 of 5 stars$74.95+1.1%$119.60+59.6%+9.5%$5.38BN/A-15.3040Earnings ReportAnalyst RevisionAXSMAxsome Therapeutics4.721 of 5 stars$103.96-0.8%$178.00+71.2%+28.9%$5.19B$385.69M-20.50380CRSPCRISPR Therapeutics3.1687 of 5 stars$55.41+0.7%$71.60+29.2%+20.0%$5.04B$37.31M-10.20460Analyst RevisionMRUSMerus1.861 of 5 stars$64.60+0.9%$88.50+37.0%+31.3%$4.89B$36.13M-11.7537Analyst RevisionABVXAbivax3.3732 of 5 stars$69.00-1.6%$92.33+33.8%+537.4%$4.38BN/A0.0061Short Interest ↑VKTXViking Therapeutics4.0805 of 5 stars$38.20+0.8%$86.92+127.6%-26.6%$4.29BN/A-24.9620Positive NewsGap DownTGTXTG Therapeutics4.3406 of 5 stars$26.39-1.2%$46.25+75.3%+31.3%$4.19B$329M71.32290ACADACADIA Pharmaceuticals3.7808 of 5 stars$24.82+0.9%$28.88+16.3%+59.9%$4.19B$957.80M18.66510Analyst RevisionKRYSKrystal Biotech4.5463 of 5 stars$137.54-0.8%$210.22+52.8%-20.3%$3.98B$290.52M27.96210 Related Companies and Tools Related Companies RNA Alternatives NUVL Alternatives AXSM Alternatives CRSP Alternatives MRUS Alternatives ABVX Alternatives VKTX Alternatives TGTX Alternatives ACAD Alternatives KRYS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AUPH) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aurinia Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aurinia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access